Cited for his groundbreaking work on the underlying metabolic causes of aging
MENLO PARK, Calif., Nov. 08, 2018 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage
biotechnology company developing mitochondria based therapeutics (MBTs) to treat age-related diseases, today announced that
co-founder and scientific advisor Dr. David Sinclair is featured among TIME Magazine’s Health Care 50, a profile of fifty
people changing healthcare in 2018. The profile cites Dr. Sinclair’s ongoing work in addressing and even reversing typical signs of
aging, including high blood pressure, weight gain and decreased metabolism. Dr. Sinclair was also featured as one of TIME
Magazine’s 100 Most Influential People in 2014.
“This recognition of Dr. Sinclair by TIME Magazine underscores his pioneering work in the field of aging,
particularly in the arena of mitochondrial genetics and the biology of aging,” said Simon Allen, Chief Executive Officer of CohBar.
“We remain grateful to Dr. Sinclair for his ongoing guidance and contributions to the significant advances being made by CohBar in
the development of mitochondrial-derived peptides to treat age-related diseases and extend healthy lifespan.”
Dr. Sinclair is a Professor in the Department of Genetics and co-Director of the Paul F. Glenn Center for the
Biology of Aging at Harvard Medical School. He is best known for his work on understanding why we age and how to slow its effects.
He obtained his Ph.D. in Molecular Genetics at the University of New South Wales, Sydney in 1995. He worked as a postdoctoral
researcher at M.I.T. with Dr. Leonard Guarente where he co-discovered a cause of aging for yeast as well as the role of Sir2 in
epigenetic changes driven by genome instability. In 1999, he was recruited to Harvard Medical School where his laboratory's
research has focused primarily on understanding the role of sirtuins in disease and aging, with associated interests in chromatin,
energy metabolism, mitochondria, learning and memory, neurodegeneration, and cancer. He has also contributed to the understanding
of how sirtuins are modulated by endogenous molecules and pharmacological agents such as resveratrol. In addition to CohBar, Dr.
Sinclair is co-founder of several biotechnology companies (Sirtris, Ovascience, Genocea, MetroBiotech, ArcBio, Liberty Biosecurity,
Life Biosciences, Spotlight, Jumpstart, and Iduna) and is on the boards of several others. He is also co-founder and co-chief
editor of the journal Aging. His work is featured in five books, two documentary movies, 60 Minutes, Morgan Freeman's
“Through the Wormhole” and other media. He has published more than 150 scientific articles, is an inventor on 35 patents, and has
received 34 awards and honors including the CSL Prize, The Australian Commonwealth Prize, Thompson Prize, Helen Hay Whitney
Postdoctoral Award, Charles Hood Fellowship, Leukemia Society Fellowship, Ludwig Scholarship, Harvard-Armenise Fellowship, American
Association for Aging Research Fellowship, Nathan Shock Award from the National Institutes of Health, an Excellence in Teaching
Award from Harvard Medical School, Ellison Medical Foundation Junior and Senior Scholar Awards, Merck Prize, Genzyme Outstanding
Achievement in Biomedical Science Award, Bio-Innovator Award, David Murdock-Dole Lectureship, Fisher Honorary Lectureship, Les
Lazarus Lectureship, Australian Medical Research Medal, The Frontiers in Aging and Regeneration Award, Top 100 Australian
Innovators, Pioneer Award from the National Institutes of Health, the Irving Wright Award, Advance Global Australian Award, a NASA
iTECH award, and TIME magazine’s list of the “100 most influential people in the world.” In 2018 he became an Officer of the
Order of Australia.
The TIME Magazine profile can be found here.
About CohBar
CohBar (NASDAQ: CWBR) is a clinical stage biotechnology company focused on the research and development of
mitochondria based therapeutics (MBTs), an emerging class of drugs for the treatment of age-related diseases. MBTs originate from
the discovery by CohBar’s founders of a novel group of peptides within the mitochondrial genome which regulate metabolism and cell
death, and whose biological activity declines with age. CohBar’s efforts focus on the development of these mitochondrial-derived
peptides (MDPs) into clinically relevant MBTs that offer the potential to address a broad range of age-related diseases with
underlying metabolic dysfunction, including nonalcoholic steatohepatitis (NASH), obesity, Type 2 diabetes, cancer, and
cardiovascular and neurodegenerative diseases. To date, the company and its founders have discovered more than 100 MDPs. For
additional company information, please visit www.cohbar.com.
Forward-Looking Statements
This news release contains forward-looking statements (statements which are not historical facts) within the
meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements regarding the
therapeutic potential of mitochondrial-derived peptides for the treatment of age-related diseases. Forward-looking statements are
based on current expectations, estimates and projections that involve a number of risks and uncertainties that could cause actual
results to differ materially from those anticipated by CohBar. These risks and uncertainties include, among other things, the
uncertainties inherent in research and development, such as the possibility of unfavorable study results, including unfavorable new
data and additional analyses of existing data; risks associated with initial data, including the risk that results of additional
pre-clinical or clinical studies may be different from (including less favorable than) the earlier data results and may not support
further clinical development of CohBar’s therapeutic candidates. Additional risks and uncertainties include CohBar’s ability to
retain key personnel, expand its research operations, and obtain financing necessary to continue its operations and fund its
candidate programs. Additional assumptions, risks and uncertainties are described in detail in our registration statements, reports
and other filings with the Securities and Exchange Commission and applicable Canadian securities regulators, which are available on
our website, and at www.sec.gov or www.sedar.com.
You are cautioned that such statements are not guarantees of future performance and that our actual results may
differ materially from those set forth in the forward-looking statements. The forward-looking statements and other information
contained in this news release are made as of the date hereof and CohBar does not undertake any obligation to update publicly or
revise any forward-looking statements or information, whether as a result of new information, future events or otherwise, unless so
required by applicable securities laws. Nothing herein shall constitute an offer to sell or the solicitation of an offer to buy any
securities.
Contacts:
Jon Stern, COO
CohBar, Inc.
(650) 446-7888
jon.stern@cohbar.com
Joyce Allaire
LifeSci Advisors, LLC
jallaire@lifesciadvisors.com
![cohbar.JPG](https://resource.globenewswire.com/media/17ec4007-256a-45a3-bb01-44b343442386/small/cohbar-jpg.JPG)
![](http://www.globenewswire.com/newsroom/ti?ndecode=NzA2NDAjNzQyNzU5NA==)